Program
human retinal progenitor cells
Its studies are mostly in Retinitis Pigmentosa, led by jCyte.
Furthest: phase 2, since Dec 16, 20144 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| jCyte | 41 open or running | phase 2since Dec 16, 2014 | Dec 16, 2014 | Dec 2026phase 2 · NCT06912633 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2014First study: phase 2 study in Retinitis PigmentosaFirst studyNCT02320812 · 28 enrolled · United States
- Mar 2, 2017Phase 2 study in Retinitis PigmentosaNCT03073733 · 84 enrolled · United States
- Oct 16, 2020Phase 2 study in Retinitis PigmentosaNCT04604899 · 30 enrolled · United States
- Mar 26, 2025Phase 2 study in Retinitis PigmentosaNCT06912633 · 31 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Retinitis PigmentosaNCT06912633
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06912633Retinitis Pigmentosa · United States | 2 | Active, not recruiting | Dec 2026 | 31 |
| NCT04604899Retinitis Pigmentosa · United States | 2 | Completed | Mar 22, 2022 | 30 |
| NCT03073733Retinitis Pigmentosa · United States | 2 | Completed | Nov 13, 2020 | 84 |
| NCT02320812Retinitis Pigmentosa · United States | 2 | Completed | Jul 19, 2017 | 28 |
How it is read
Names in the registry
- “human retinal progenitor cells”, 4 entries
Conditions, from the studies’ own filings
- Retinitis Pigmentosa, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.